CEO Sean McCarthy told BioWorld Today that Cytomx Therapeutics Inc.'s deals will be "increasingly strategic," structured for purposes of "not just bringing cash in the door," and the latest – the firm's third pharma pact – with Abbvie Inc. typifies what he's talking about: "a foundational, pipeline-building" arrangement.